Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orca Pharmaceuticals Ltd.

www.orcapharmaceuticals.com

Latest From Orca Pharmaceuticals Ltd.

Deal Watch: Genzyme Validates Alnylam's Strategy By Partnering On Hemophilia Candidate

Astellas/Chromocell pain therapy collaboration centers on New Jersey biotech's platform technology, which may solve the problem of reproducing Nav1.7 receptors for in vitro assays. Xoma signs preclinical immuno-oncology partnership with Novartis, dimming the focus on Phase III flop for gevokizumab.

BioPharmaceutical Deals

Biopharma Quarterly Dealmaking Statistics, Q1 2015

Biopharma financing reached $15.1 billion, with record-breaking FOPO dollar volume making up close to $10 billion of the total; AbbVie topped the $66.5 billion M&A activity with its $20 billion buy of Pharmacyclics; and gastroenterology was one of the most highly partnered therapeutic areas.

BioPharmaceutical Deals

Deals Shaping The Medical Industry, March 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, Pharmaceuticals, and Research/Analytical – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced February 2015.

BioPharmaceutical Medical Device

Deal Watch: Immuno-Oncology Double-Header At Bristol With Rigel, Flexus Deals

Valeant jumps back into M&A, acquiring Salix after wholesale inventory issues discouraged other potential buyers. Merck more or less options a pipeline with its five-year R&D collaboration with NGM Pharma.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Gastrointestinal
  • Immune Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Orca Pharmaceuticals Ltd.
  • Senior Management
  • Michael Hunter, PhD, CEO
    Roy Pettipher, PhD, CSO
  • Contact Info
  • Orca Pharmaceuticals Ltd.
    Phone: 1235 841542
    The Innovation Ctr., 99 Park Dr.
    Milton Park
    Abingdon, OX14 4RY
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register